Pancreatic Cancer
Conditions
Interventions
None listed
Sponsors
Ono Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with pancreatic cancer Patients who received FOLFIRINOX or GEM + nabPTX as initial chemotherapy Patients who have 2 body weight data recorded: body weight data as of the start date of the first chemotherapy and body weight data that exist 6 months (183 days) prior to the start of the first chemotherapy
Exclusion criteria
Exclusion criteria: Pancreatic cancer stage < 3 on the first day of initial chemotherapy Patients who received initial chemotherapy < 60 days followed by surgery Patients who have undergone surgery for pancreatic cancer between the most recent diagnosis of pancreatic cancer and the start of initial chemotherapy. Relapsed patients without initial surgery Relapsed patients without initial information Relapsed patients without initial postoperative chemotherapy Recurrence less than 183 days after completion of initial postoperative chemotherapy Patients with recurrent pancreatic cancer of stage 3 or higher at the initial onset who have received preoperative chemotherapy for at least 60 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence/absence of discontinuation/completion of initial chemotherapy (1st line) and number of days until that | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence/absence of discontinuation/completion of initial chemotherapy (1st line) and the number of drug prescriptions before that Overall Survival (OS) etc | — |
Countries
Japan
Contacts
Public ContactKoji Machii
Ono Pharmaceutical Co., Ltd. Oncology Medical, Medical Affairs
Outcome results
None listed